LegalView Alerts Readers of a Pain-Relief Patch That Has Been Linked to 120 Deaths Among Patients

Share Article

LegalView immediately launched a practice area detailing the recall of a pain-relieving patch that has been associated with patient overdoses. The Duragesic patch was recalled because of a manufacturing defect that caused many of the patches to leak.

LegalView recently launched the Duragesic patch recall information portal after manufacturers of the pain-relieving patch recalled the drug because of a serious manufacturing defect in the 25 microgram per hour patch that has been associated with patient overdoses, according to press reports that quote a Food and Drug Administration (FDA) spokesperson. The Duragesic patch is used for long-term relief of moderate and severe pain and the patch releases a pain reliever known as fentanyl over a 72-hour period. The patches, which are manufactured by a division of Johnson & Johnson, have received many U.S. FDA warnings since the patch's approval in late 2000.

The company has also voluntarily recalled the patch several times prior to the most recent recall, which occurred in February. The most recent voluntary Duragesic recall will likely involve nearly 32 million patches, which may or may not also have the manufacturing defect. Individuals currently receiving a prescription of the patch should contact a Duragesic attorney to learn more about the Duragesic patch recall.

Additionally, Duragesic patch side effects may also adversely affect individuals and those taking the medication should watch for these side effects, which can include addiction or physical dependence on the pain reliever, hypotension, nausea, weakness and drowsiness, according to the FDA.

Other prescription drug practice areas available through LegalView's information portals include Trasylol, which is a blood clotting agent often used in surgery. Trasylol was voluntarily recalled by its manufacturer as a result of a study published on January 26, 2006 in The New England Journal of Medicine (NEJM), which showed that the drug may be associated with increased risk of myocardial infarction, stroke and renal dysfunction among patients, when compared with an alternative clotting agent. Most recently, Trasylol was put in the spotlight by a 60 Minutes segment aired on CBS that discussed how the manufacturer may not have reported the results of the NEJM study to the FDA in an expedient manner. As a result, many readers may want to contact a Trasylol attorney for more information.

Another drug discussed in a LegalView practice area is Heparin, a blood thinner that is administered during medical procedures, such as kidney dialysis as well as heart surgery. Heparin is highly effective and has been used since shipments began in the 1930s. Recently, LegalView created the Baxter Heparin information portal to help readers learn more about this drug.

Also, readers can use LegalView's practice area to learn about potentially serious Avandia side effects that can affect those taking this diabetes medication. Avandia is prescribed to individuals battling type 2 diabetes. However, it has been discovered that Avandia may increase the risk of cardiac arrest among patients taking the drug, as cited in a May 2007 FDA warning. Additionally, a study published by the Salk Institute in December 2007 found that Avandia may also speed up the process of osteoporosis.

About LegalView: is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Katie Kelley

Alan Haburchak
Visit website